



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : G01N 33/53, 33/92, 33/531 G01N 33/533, 33/534, 33/566 C12Q 1/60, 1/48		A1	(11) International Publication Number: WO 86/03299 (43) International Publication Date: 5 June 1986 (05.06.86)
(21) International Application Number: PCT/US85/02274 (22) International Filing Date: 20 November 1985 (20.11.85)		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(31) Priority Application Number: 673,768 (32) Priority Date: 21 November 1984 (21.11.84) (33) Priority Country: US		Published <i>With international search report.</i>	
(71)(72) Applicant and Inventor: SCHAFFNER, Carl, P. [US/US]; 10 Youngs Road, Trenton, NJ 08619 (US).			
(74) Agents: SUYAT, Reginald, J. et al.; Flehr, Hohbach, Test, Albrton & Herbert, Four Embarcadero Center, Suite 3400, San Francisco, CA 94111-4187 (US).			
(54) Title: METHOD FOR IMMUNOANALYSIS OF CHOLESTEROL EPOXIDES			
(57) Abstract			
<p>An immunoassay for cholesterol epoxide. To prepare the antibodies used in the immunoassay, novel immunogens, are prepared which comprise a 3,5(6)-transdialxial-dihydroxycholestane-6(5)-yl-hapten adduct linked to a covalently bonded bridge to a carrier protein. To detect cholesterol epoxide in the sample, it is converted to the hapten adduct, then contacted with the selected antibody.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BD	Bolivia	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	L1	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

METHOD FOR THE IMMUNOANALYSIS OF
CHOLESTEROL EPOXIDES

This invention is directed to a specific and precise method for the qualitative and quantitative analysis of cholesterol epoxides in biological products, secretions, fluids and tissues by employing a combination of enzymatic or chemical
5 and immunological procedures.

BACKGROUND OF THE INVENTION

The present invention relates in part with the observations that the cholesterol epoxides are found in animal products arising either metabolically or by autoxidation. In the presence of molecular oxygen and light cholesterol readily
10 autoxidizes to form predominantly cholesterol 5 β , 6 β -epoxide and a minor proportion of the isomeric, cholesterol 5 α , 6 α -epoxide. The degree of autoxidation increases with time and temperature. The cholesterol epoxides, thus, are found in aged cholesterol-rich products, such as dried
15 egg products.

Of major importance, however, are the cholesterol epoxides which form metabolically in a variety of organs and tissues, such as the liver, male prostate gland, and female breast. As highly transient metabolic intermediates in the pathway from cholesterol to cholestane 3 β , 5 α , 6 β -triol, a suspected regulator of endogenous cholesterol synthesis, the cholesterol epoxides normally never accumulate nor are they generally detectable with analytical procedures currently available to clinical scientists.
20

However, associated with various pre-developmental or existing pathological states, the cholesterol epoxides do accumulate in the related tissues and secretions. Initially, as a dose-dependent response cholesterol 5 α , 6 α -epoxide was detected in the skin of humans and animals after exposure to ultraviolet irradiation. Likewise the cholesterol epoxides are present in the serum of patients suffering with familial hypercholesterolemia where the serum cholesterol levels are also elevated. Tissue epoxy-cholesterol accumulation has also been seen in the rare but fatal Wolman's disease.

Of major importance is the more recent observation that the cholesterol epoxides are found in the tissues and secretions of the aging human prostate gland. This observation is particularly consistent with the development of benign and malignant diseases. The epoxycholesterols have also been observed with aging in female breast secretions and are associated with the high risk category for development of breast cancer. The female breast and male prostate are both hormone-regulated glandular secretory organs producing significant quantities of cholesterol. Significant increases of the cholesterol content of serum, prostate tissues and breast aspirates are now associated with the appearance of the epoxycholesterols, suggesting some loss of regulation of cholesterol synthesis and metabolism.

The possible role of cholesterol and its metabolites in mutagenesis and carcinogenesis has long been a controversial subject. The earliest observation revealed the production of sarcomas and other tumors when cholesterol epoxides were administered subcutaneously to experimental animals. The formation of tumors after ultraviolet irradiation of skin has been correlated with the initial formation of cholesterol 5 α , 6 α -epoxide. Likewise, cholesterol epoxides, due to the angiotoxicity of oxygenated sterols and not cholesterol itself, are suspect in the development of arterial wall damage leading to the eventual

emergence of atherosclerotic lesions and cardiovascular blockage.

There is sufficient evidence that the cholesterol epoxides produce a similar degree of chromosome damage and DNA repair synthesis as low doses of ultraviolet irradiation. 5 Cholesterol 5 α , 6 α -epoxide forms a strong physical bond with DNA leading to significant covalent attachment of the steroid to this macromolecule. Likewise, it has been demonstrated with hamster embryonic cells that cholesterol 10 5 α , 6 α -epoxide is as potent a carcinogen as the well recognized 3-methylcholanthrene. This cholesterol metabolite has also been implicated as an etiologic agent 15 in human colon cancer.

In considering that many well known exogenous carcinogens 15 undergo metabolic activation to the electrophilic "ultimate carcinogen" by endogenous metabolic epoxidation reactions, it would be expected that the electrophilic cholesterol epoxides may also play an important role in a wide variety 20 of cytotoxic, mutagenic and carcinogenic physiological reactions. Their detection and quantitation in biological fluids and tissues has become of increasing importance in 25 clinical medicine.

The consistent presence of the epoxycholesterols in prostatic secretions may be diagnostic for the development of 25 both benign and malignant diseases of the human and canine prostate gland. Likewise, detection of the cholesterol epoxides in female breast aspirates may be associated as a risk factor for the development of benign breast disease and breast cancer. Since the cholesterol epoxides are 30 detected in the serum of patients suffering with familial hypercholesterolemia which normally results in early death due to advanced atherosclerosis, the appearance of these cholesterol metabolites in serum may serve as an important risk factor for the development of coronary vascular disease.

The qualitative and quantitative measurement of the cholesterol epoxides in biological fluids and tissues due to their relatively low concentration has been a difficult, costly and time-consuming task. The procedures of thin layer chromatography, high performance liquid chromatography, gas-liquid chromatography, nuclear magnetic resonance spectrometry, and mass spectrometry have all been employed either alone or in combination for the detection, 5 characterization and quantitative measurement of the cholesterol epoxides in different biological fluids and tissues. While important in research projects as experimental 10 procedures, these do not lend themselves readily to routine, quick, precise and economical clinical analyses in medical practice.

15 A usual procedure for the development of the immunoassay for cholesterol epoxides might follow a series of well-established methods. Normally, cholesterol epoxide, itself not antigenic as a "hapten", would be complexed through stable covalent bonds to a normally antigenic molecule such as a protein. Protein "carriers", such as bovine serum 20 albumin, ovalbumin and bovine gamma globulin are often employed for this purpose. The cholesterol epoxide-protein complex or "immunogen" would then be introduced to the blood of some living experimental animal such as the mouse, 25 rat or rabbit. With the recognition of the presence of a foreign antigenic substance, the animal in turn would then consequently produce a specific protein called "antibody" which has the specific ability to complex with the foreign cholesterol epoxide-containing protein or with cholesterol 30 epoxide itself. The production of this specific antibody by the animal is the essential step in the development of an immunoassay test procedure for cholesterol epoxide. The isolation of this specific antibody protein from the blood 35 of the animal would enable the preparation of one essential component or reagent of the immunoassay test procedure.

The reaction of the cholesterol epoxide specific antibody protein with the test product whether in serum or in breast or prostatic secretions would result in the formation of complexes that can be isolated. If the test product, 5 cholesterol epoxide, is labelled with some enzyme or radioactive element, the amount of the label in the resultant complex then depends on the amount of product that was added for a fixed amount of standardized reagent antibody. If one combines labelled test product, as a known reference, 10 with an unknown sample from a test patient, the product in the test sample will compete with the labelled reference product in reacting with the antibody. This will result in a decrease in the amount of label combined with the antibody. This decrease usually provides a sensitive and 15 precise measure of the product, cholesterol epoxide, in the test sample of the patient. Thus, the cholesterol epoxide specific antibody protein and the enzyme - or radioactive-labelled cholesterol epoxide test product are the essential components of an enzyme-immuno or radioimmuno assay test 20 procedure, respectively.

Immunoassay test procedures whether based on enzyme or radioactive element-linked antibody assays are ordinarily extremely sensitive, highly specific, and rapid by nature. While such procedures are not usually employed for the 25 quantitation of cholesterol, itself, they are currently widely employed for the clinical analysis of other cholesterol-derived molecules, such as the steroid hormones, testosterone, 5 α -dihydrotestosterone, estradiol, estrone, estriol-17 β , cortisol and cortisone which like the cholesterol epoxides are normally only present in small quantities in biological fluid and tissues.

30 However, there is a complication encountered in the immuno-assay of particular steroid hormones in that there is usually cross-reactivity of other steroids of related or similar molecular structure. As an example, antiserum for 35 estradiol-17 β could exhibit percentage cross-reaction of

94,61, and 19 for estrone, estradiol-17 α , and estriol-17 β , respectively. In considering the concentration of the cholesterol epoxides in biological fluids such as serum and breast or prostatic secretions, one always finds a most significant excess of cholesterol as well. As much as a 40-100 fold greater concentration of cholesterol is usually found as compared to that of the cholesterol epoxides. Thus, with the preparation of antibodies directed towards the intact cholesterol epoxide-protein immunogen, it would be expected that cholesterol itself would exhibit some cross-reactivity with this antibody. This would reduce the usefulness of the immunoassay procedure for the cholesterol epoxides by virtue of the possibility that cholesterol itself would react, leading to false positive results.

It is therefore an object of the present invention to provide a clinical diagnostic method for the qualitative and quantitative measurement of the cholesterol epoxides based on immunological or immunoassay procedures.

SUMMARY OF THE INVENTION

The present invention provides a clinical diagnostic method for qualitatively and quantitatively measuring the presence of cholesterol epoxide. The method of preparation of the materials used in the diagnostic method utilizes a specific cholesterol epoxide reaction to produce a novel cholesterol epoxide adduct molecule, structurally highly different from that of cholesterol, cholesterol epoxide, and other related steroid molecules normally present in biological fluids and tissues. In a preferred embodiment, the enzyme, S-glutathione transferase, of the mammalian liver soluble supernatant fraction is employed to convert cholesterol 5 α , 6 α -epoxide to the S-glutathione conjugate, 3 β , 5 α -dihydroxy-cholestan-6 β -yl-S-glutathione. This conjugate as a hapten is linked through stable covalent bonding to a protein carrier, such as bovine serum albumin, to produce an immunogen suitable to initiate an immune response. The resultant antibodies are sensitive and specific to the

cholesterol epoxide-glutathione adduct product rather than to cholesterol epoxide itself. One or more of these antibodies may be selected for use in an immunoassay for the adduct.

5 The resultant antibodies, either polyclonal or monoclonal, are thus used to provide a method for determining the presence or concentration of cholesteryl epoxide in a sample of fluid. The sample will first be contacted with a 10 hapten (preferably glutathione) in the presence of a hapten-linking agent (preferably, S-glutathione transferase) to form a ring-opened 3,5(6)-trans-diaxial-dihydroxycholestane-6(5)-yl-hapten adduct. The adduct may be detected or assayed by immunoassay procedures using the prepared antibodies.

DESCRIPTION OF THE INVENTION

15 Glutathione (γ -glutamyl-cysteinyl-glycine) as a thiol-nucleophile is the primary substrate of S-glutathione transferase activity. This tripeptide metabolite is normally found in virtually all cells. It is an unusual tripeptide since the N-terminal glutamate is attached to 20 cysteine via a non- α -peptidyl bond. Normally glutathione performs a wide range of metabolic functions, generally "protective" by nature. Involved in detoxification reactions it protects living cells from oxidative and free radical interactions. The initial step in the detoxification 25 pathway involves reaction of the foreign toxic compound with the SH-group of glutathione to form an S-substituted glutathione derivative. Although these reactions proceed enzymatically with the S-glutathione transferases, some can also proceed chemically without 30 enzyme.

As a normal detoxification reaction of the liver the interaction of cholesterol 5 α , 6 α -epoxide with glutathione is mediated by rather specific soluble S-glutathione transferases, identified in the rat liver as two forms of

S-glutathione transferase B. Generally, the S-glutathione transferases are fairly nonspecific group of soluble enzymes. In this connection, however, they appear to possess rather broad and overlapping substrate specificities. With cholesterol 5 α , 6 α -epoxide as an electrophilic substrate, primarily only S-glutathione transferase B fractions exhibit enzymatic activity. These rather specific enzymes, as cytosol-soluble, basic liver proteins, constitute a significant portion of the soluble protein fraction of the liver. With a molecular weight of approximately 45,000 glutathione S-transferase B consists of two protein subunits of approximately equal molecular weight.

Aside from glutathione and cholesterol epoxide as substrates the enzymatic reaction with S-glutathione transferases does not require the initial formation of high energy intermediates where the participation of ATP in the reaction is necessary. The specificity of S-glutathione transferase B for cholesterol 5 α , 6 α -epoxide is rather unique.

Pure cholesterol epoxides are not generally available from commercial sources, so they were synthesized from cholesterol. Analytical grade cholesterol, purified through the dibromide, was employed in these syntheses. Cholesterol 5 α , 6 α -epoxide was synthesized by the procedure of Fieser, L.F. and Fieser, M., in "Reagents for Organic Synthesis," Vol. 1, 1967 John Wiley, New York, p. 136. Cholesterol (50 mmol) in methylene chloride (75 ml) solution was treated at 25°C over a 30 minute interval with m-chloroperbenzoic acid (54 mmol) in methylene chloride (120 ml) solution. Excess peracid was destroyed by the addition of 10% sodium sulfite. Extraction of the organic layer with 5% aqueous sodium bicarbonate, water, and finally with saturated aqueous sodium chloride, followed by drying and evaporation produced a crude product readily purified by recrystallization from 88% aqueous acetone or by silica gel chromatography. Cholesterol 5 α , 6 α -epoxide (>95% purity, m.p.

142-143°) was obtained in >90% yield.

Cholesterol 5 β , 6 β -epoxide was synthesized from cholesterol by the procedure of Tohma, M., Tomita, T., and Kimura, M., Tetrahedron Letters 44, 4359-4362 (1973). As described, 5 30% hydrogen peroxide (5.5 ml.) was added dropwise to a solution of cholesterol (100 mg) and ferric acetylacetone (930 mg) in acetonitrile (100 ml) with stirring at 40°C. Excess hydrogen peroxide was destroyed with saturated aqueous sodium sulfite, and the organic phase was extracted 10 with ethyl ether (50 ml. x 3).

The combined organic layer was washed with saturated aqueous sodium chloride and dried with anhydrous sodium sulfate. The residue obtained after vacuum evaporation was purified by liquid chromatography on silica gel employing 15 gradient elution with benzene acetone. Select fractions containing cholesterol 5 β , 6 β -epoxide were pooled and evaporated. Recrystallization from aqueous acetone produced cholesterol 5 β , 6 β -epoxide (m.p. 131-134°) in 60% yield.

20 As components of radioimmune assay test procedures, radio-labelled cholesterol 5 β , 6 β -epoxide and cholesterol 5 β , 6 β -epoxide were also prepared from readily available radiolabeled cholesterol starting material employing the 25 procedures outlined above. Both tritium - and carbon-14 labelled cholesterol epoxides of high specific activity were prepared in this manner.

The capability of the immune system of an animal to respond to foreign antigens is strongly dependent on the molecular size of the antigen. Steroids such as the cholesterol 30 epoxides with low molecular weights are unable by themselves to elicit antibody production. However, as haptens and as part of a macromolecular structure (immunogen) involving a protein carrier unit, the cholesterol epoxides and their derivatives as such can induce the immune system

to produce antibodies that react in vitro with the hapten itself. Immunogens containing cholesterol 5 α , 6 α -epoxide or cholesterol 5 β , 6 β -epoxide as haptens enable the production of antibodies that react as well but to a lesser degree with cholesterol and other closely related molecules such as cholestane 3 β , 5 α -diol, cholestane 3 β , 6 β -diol, or cholestane 3 β , 5 α , 6 β -triol. The unique electrophilic reactivity of the cholesterol epoxides allows the use as haptens compounds derived solely directly from the reactive cholesterol epoxides. These derivatives have molecular structures sufficiently different from that of the cholesterol epoxides and cholesterol so as to impart specificity to the antibodies produced after immunization. The unique interaction of the cholesterol epoxides with glutathione, whether by chemical or enzymatic reactions, produces S-glutathione conjugates that serve as such selective haptens.

Other conjugates with cholesterol epoxide may be formed which are within the scope of the present invention. The cholesterol epoxides by virtue of their electrophilic character can undergo reaction with a wide variety of nucleophiles, other than S-glutathione, producing in many cases derivatives widely different from the parent compounds. Reactions with water and simple low molecular weight alcohols, however, would still result in products somewhat structurally related to the cholesterol epoxides. Interaction of cholesterol 5 α , 6 α -epoxide and cholesterol 5 β , 6 β -epoxide with water (hydrolysis) results in the formation of the identical product, cholestane 3 β , 5 α , 6 β -triol. Similar transdixial cleavage of the cholesterol epoxides with other nucleophiles of more complex structure and higher molecular weight produces derivatives with structures more widely different from that of cholesterol and its reactive epoxides. Cholesterol 5 α , 6 α -epoxide reacts with benzenethiol (thiophenol) in the presence of catalytic amounts of phosphoric acid to yield via transdixial ring opening, 3 β , 5 α -dihydroxycholestane

5 6 β -S-yl-thiophenol. Cholesterol 5 β , 6 β -epoxide produces in this reaction 3 β , 6 β -dihydroxycholestane 5 α -S-yl-thiophenol. Cholesterol 5 α , 6 α -epoxide will also react with imidazole to form the 3 β , 5 α -dihydroxycholestane 10 6 β -imidazole adduct. The cholesterol epoxides can thus react with a wide variety other nucleophiles to produce by transdixial epoxide ring opening the corresponding steroid conjugate adduct. Many of these reactions may thus be employed to produce specific derivatives of the cholesterol epoxides which serve as haptens in the construction of immunogens useful for the preparation of antibodies with unique specificity for these derivatives.

15 In the present invention the cholesterol epoxide-nucleophile reaction product or conjugate serves as the hapten. The preferred hapten is the glutathione reaction product with cholesterol 5 α , 6 α -epoxide, namely, 3 β , 5 α -dihydroxycholestane 6 β -S-yl glutathione which serves as a hapten.

20 In accordance with the present invention, the hapten is further attached to a protein carrier by covalently bonded bridge molecules such as the hemisuccinate, α -carboxymethyl ether or similar structures involving the 3 β -hydroxyl group of the A steroid ring, leaving the intact determinant (for example, glutathione) attached to the B ring unaltered. 25 Loss of immunological specificity to the A steroid ring structure in the resultant antibody after immunization is believed to be of small consequence since many steroids like cholesterol have structural determinants in this part of the steroid molecule similar to the cholesterol epoxides. The immunological determinants pertinent to this 30 invention for the reaction products of cholesterol 5 α , 6 α -epoxide reside primarily in the 6 β position of the B ring whereas that of the products derived from cholesterol 5 β , 6 β -epoxide reside in the 5 α position between the A and 35 B rings.

The selection of the immunogenic protein carrier is generally not critical. The preparation of an immunoassay procedure according to the invention is exemplified below using bovine serum albumin as the carrier protein. With an assumed molecular weight approximating 70,000, bovine serum albumin contains about 61 terminal amino groups, not all of which are directly accessible due to protein folding. Aside from this rather well-defined protein, other protein carrier molecules can also be utilized, such as rabbit serum albumin, myoglobin, lysozyme hemoglobin, and so forth.

The attachment to the immunogenic protein carrier to the haptens, cholesterol 5 α , 6 α -epoxide and cholesterol 5 β , 6 β -epoxide or their reaction products with nucleophiles, may be attained through a hydrocarbon bridge, such as a succinyl bridge. Initially, both cholesterol 5 α , 6 α -epoxide hemisuccinate and cholesterol 5 β , 6 β -epoxide hemisuccinate were obtained by interaction of both epoxycholesterols with succinic anhydride in pyridine solution. An alternate method of joining the steroid derivative molecule to the protein carrier is the use of the O-carboxymethyl ether bridge. The 3 β hydroxyl group of the cholesterol epoxides under certain conditions will react with ethyldiazoacetate or with ethyl bromoacetate to yield the O-carboxymethyl ether derivative as the ester. Alkaline saponification will then yield the 3 β -O-carboxymethyl ether derivative of the cholesterol epoxides. This cholesterol epoxide bridge compound is more stable to alkaline hydrolysis than the hemisuccinate cholesterol epoxide derivatives. Other covalently-bonded bridges between the steroid hapten molecule and the protein carrier may also be used, such as disulfide, diol, diester, dicinide bridges, and so forth.

In a preferred preparation of the immunogen molecule, the cholesterol epoxide hemisuccinates or the corresponding 3 β -O-carboxymethyl ether derivatives and their nucleophile

derivatives may be chemically coupled to the terminal amino residues of the protein carrier, such as bovine serum albumin. A number of different coupling reactions may be employed. Preferably, the carbodiimide reaction is used to 5 join the carboxyl group to the terminal amino group of the protein molecule forming a stable peptide bond. Other reactions, such as the mixed anhydride reaction, may also be employed to join the carboxyl group to the terminal amino group. Since the epoxide structure is sensitive to 10 acidic conditions, it is desirable to carefully control the pH during chemical reactions involving the intact cholesterol epoxides.

The overall immune response to a steroid-protein conjugate is dependent on the molar ratio of steroid to protein in 15 the immunogen. On the bovine serum albumin molecule not all of the amino groups are available for chemical substitution since several are masked by molecular folding so molar ratios of steroid to protein frequently range, between 15:1 and 30:1. Thus, there may not always be clear 20 evidence of a direct correlation between the steroid-protein ratio and the titer, specificity, and affinity of the antisera directed towards the steroid hapten.

The final immunogen for the preparation of specific antibodies in the scope of this invention comprises the 25 cholesterol epoxide nucleophile reaction product (hapten) covalently bonded to the protein carrier through a bridge involving the 3β hydroxyl group of the steroid molecule and the terminal amino groups of the protein. In the preparation of a preferred immunogen involving the hapten, 3β , 5 α -dihydroxycholestane-6 β -S-yl-glutathione, either the 30 cholesterol 5 α , 6 α -epoxide-3 β -O hemisuccinate or the cholesterol 5 α , 6 α -epoxide-3 β -O-carboxymethyl ether derivative is condensed with the protein carrier, bovine serum albumin by the carbodiimide reaction. Finally, the epoxide 35 functional groups of the protein bound material are reacted with glutathione to yield the ultimate immunogen. Direct



-14-

carbodiimide condensation of the hapten itself, 3 β , 5 α -dihydroxycholestane 6 β -S-yl-glutathione, to the protein carrier is also possible, but less preferable due to the potential reactivity of the carboxyl groups of the 5


glutathione moiety. However, other cholesterol epoxide-nucleophile reaction products with nucleophile-derived structural determinants unreactive in the carbodiimide condensation process may be coupled directly to the protein carrier to form the final immunogen.

10 A summary of the construction of useful haptens and immunogen molecules necessary for the production of specific antibodies directed to the cholesterol epoxide-nucleophile reaction product as haptens may be reviewed as follows:


Preparation of Cholesterol Epoxide-Nucleophile Haptens



-15-

Construction of Immunogen Molecule

The nucleophile can be reacted with the epoxide ring of the cholesterol epoxide moiety either with the free cholesterol epoxide, its bridge derivative or with the cholesterol epoxide-containing immunogen, dependent on the nature of the nucleophile.







Adduct I is then bridged and finally coupled to protein to form the immunogen.

10 Adduct II is directly coupled to protein to form the immunogen.


Nucleophiles (HX)

A wide variety of nucleophilic substances can react with the electrophilic epoxides of cholesterol. Acidic conditions generally increase the electrophilic character of the epoxide. Different groups of sulfur, nitrogen, and oxygen-containing nucleophilic reagents may be cited.





Sulfur-Containing Nucleophiles - Thiols




-17-




Nitrogen-Containing Nucleophiles






-18-


(piperolic acid)




(pyrrolidine)




(3-pyrroline)



(piperazine)




(amino acids)

Organic Acids


(p-toluenesulfonic acid)



(trifluoroacetic acid)

Alcohols

(phenol)




(cresols)




(alkylalcohols)

Purines, Pyrimidines, Nucleosides and Nucleotides





Pyrimidine




Purine





(6-aminopurine)

Cytosine
(2-oxy-4-aminopyrimidine)Guanine
(2-amino-6-oxypurine)Uracil
(2,4-dioxypyrimidine)



2-Methyladenine




5-Methyladenine


Thymine
(5-methyl-2,4-dioxypyrimidine)

1-Methylguanine 5-Hydroxymethylcytosine







Adenosine 5'-phosphoric acid
(adenylic acid; 5'-adenylic acid)




Adenosine 2'-phosphoric acid
(2'-adenylic acid)




Adenosine 3'-phosphoric acid
(3'-adenylic acid)



Adenosine 3',5'-phosphoric acid
(cyclic adenylic acid)




Ribonucleoside
5'-monophosphates



Adenosine 5'-phosphoric acid
(adenylic acid; AMP)

2'-Deoxyribonucleoside
5'-monophosphates



Deoxyadenosine 5'-phosphoric acid
(deoxyadenylic acid; dAMP)

Guanoside 5'-phosphoric acid
(guanylic acid; GMP)

Deoxyguanosine 5'-phosphoric acid
(deoxyguanylic acid; dGMP)

Cytidine 5'-phosphoric acid
(cytidylic acid; CMP)

Deoxycytidine 5'-phosphoric acid
(deoxycytidylic acid; dCMP)


Uridine 5'-phosphoric acid
(uridylic acid; UMP)

Deoxythymidine 5'-phosphoric acid
(deoxythymidylic acid; dTMP)

Ribonucleoside
5'-mono, di-, and triphos-
phates

Base Abbreviations

Adenine	AMP	ADP	ATP
Guanine	GMP	GDP	GTP
Cytosine	CMP	CDP	CTP
Uracil	UMP	UDP	UTP



Deoxyribonucleoside
5'-mono, di-, and tri-
phosphates


Adenine	dAMP	dADP	dATP
Guanine	dGMP	dGDP	dGTP
Cytosine	dCMP	dCDP	dCTP
Thymine	dTMP	dTDP	dTTP

-22-


More Complex Nucleotide Derivations

Coenzyme A

Dinucleotide coenzymes.



Cholesterol epoxide interaction with DNA has been clearly demonstrated.



The selection of a suitable nucleophile for the interaction with the cholesterol epoxides is dependent on the reactivity of the nucleophile and the specificity of the reaction. Many nucleophiles such as the nucleic acids DNA and RNA have multiple sites of interaction. Simpler nucleophiles with a single major site of interaction with the cholesterol epoxides is preferable. In the analysis of biological specimens for cholesterol epoxide content it is also important that the conversion of any epoxide through interaction with the nucleophile be complete and readily and conveniently carried out under clinical laboratory conditions. In this regard, the interaction of the cholesterol epoxides with glutathione can be carried out under simple conditions either by enzymatic or chemical means. The resultant product is known, and as a hapten it is specifically recognized by the antibodies produced in its presence. Interaction of the cholesterol epoxides with thiophenol and imidazole also involves single specific sites. With clinical specimens these reactions can also be employed for conversion of any cholesterol epoxide present to the respective nucleophile product. Hence, the preparation of the cholesterol epoxide-nucleophile reaction product as a pure hapten and eventually coupling to an antigenic protein carrier as the final immunogen, all depend on the specificity and degree of the nucleophile-cholesterol epoxide reaction. With incomplete reactions the desirable immunogen may be obtained after purification.

After final synthesis of the immunogen, it will be purified and characterized. The steroid-nucleophile protein complexes obtained by any of the above described methods may be purified by conventional techniques to be freed from any steroid nucleophile product not covalently bound. Preferably, this may be achieved by dialysis against a constant flow of distilled water or by G-25 sephadex gel filtration. After purification, the immunogen conjugates are characterized to establish the molar ratio of hapten vs. carrier. Depending on the structural nature of the

5 nucleophile interacted with the cholesterol epoxides, a variety of different methods involving direct ultraviolet-visible spectrophotometry, radioisotopic incorporation or hydrolytic cleavage of the immunogen may all be applied to determine the hapten vs. protein ratios.

10 With the availability of a suitable immunogen a great variety of well established immunization procedures can be employed for the production of antibodies specific for the hapten, specifically, the cholesterol epoxide-nucleophile reaction product. The prepared immunogen in a suitable vehicle, such as saline or oily adjuvant emulsion, can be administered by multiple intradermal, subcutaneous or intramuscular administration. Antibody response is usually 15 relatively rapid. While almost all routes of administration such as subcutaneous, intramuscular, intravenous, and into the lymph nodes or footpads are utilized in conjunction with subsequent booster injections, it is found that multiple-site intradermal immunization yields satisfactory results without booster injections of immunogen. A great variety of animal species have been employed for the 20 immunization process, including the mouse, rat, guinea pig, rabbit, sheep, goat and horse.

25 The polyclonal antibodies produced by immunization of an animal with the hapten-protein immunogen can then be recovered from the serum by known techniques. During the immunization process levels of hapten specific antisera will be monitored by bleeding the animals at regular intervals. Antisera diluted with buffers are allowed to react with hapten, and upon incubation, the reaction 30 results in the formation of antibody-hapten complexes that may be measured and isolated by known techniques.

35 Monoclonal antibodies specifically directed to particular cholesterol epoxide-nucleophile haptens may also be prepared. The B lymphocytes are involved in the production of specific antibodies upon immunization of an animal. In

the monoclonal method one fuses or hybridizes two somatic cells, one belonging to a neoplastic myeloma cell line and the other consisting of a normal antibody-producing B lymphocyte obtained from the immunized animal. The 5 resulting fused cell or hybridoma retains the capacity for continuous growth from the neoplastic parent and the ability to secrete antibodies to the immunizing haptene-containing immunogen from the B-lymphocyte. Derived from a single B lymphocyte the hybridoma cell line produces only 10 one kind of antibody. Selection of the specific hybridoma cell line producing antibodies directed only to the cholesterol epoxide-nucleophile haptene may be performed by known techniques, thereby providing continuous availability of the essential component of the immuno-assay test kit.

15 The immunoassay test procedure for the detection and measurement of cholesterol epoxides depends on the anti-body-hapten reaction and, in particular, on the preparation of antibodies specific for cholesterol epoxide-nucleophile reaction products as haptens rather than for the cholesterol epoxides themselves. It is requisite for the immunoassay that any cholesterol epoxide present in biological specimens be converted by enzymatic or chemical means 20 to the nucleophile reaction product recognizable by the antibody. The same reagents may be used for this purpose 25 as are used to make the original haptene used for raising the antibodies.

In order to make the antigen (hapten)-antibody reaction measurable or visible, it is necessary to tag either the antigen or antibody with a molecule demonstrable through some special inherent property such as light emission 30 (fluorescent antibody technique), enzymatic activity (enzyme immunoassay), high electron-scanning capacity (immunoferritin method), or radioactivity (radioimmuno assay).

For enzyme immunoassay procedures the hapten specific antibody may be labelled by attaching an enzyme, such as horseradish peroxidase. This enzyme may be attached to the antibody protein via bifunctional reactants such as 5 4,4'-difluoro-3,3'-dinitro-phenylsulfone or glutaraldehyde. The enzyme conjugated antibodies can then react with the hapten and unbound antibodies are removed by washing. The hapten-antibody complex upon reaction with hydrogen peroxide in the presence of electron donors such as diamino 10 benzidine produces measurable color reactions.

In a similar manner the hapten (antigen) may also be labelled with an enzyme. Glucose 6-phosphate dehydrogenase is a frequently used labelling enzyme. When the enzyme-labelled hapten binds to the antibody specific for the 15 hapten, the enzyme activity is reduced. In a typical competitive immunoassay, hapten in the biological sample competes with the enzyme-labelled hapten for the antibody, thereby reducing the inactivation of the enzyme induced by the antibody. Glucose-6-phosphate dehydrogenase activity 20 correlates with the concentration of the hapten and is measured spectrophotometrically due to the enzymic catalysis of the substrate NAD to NADH.

When using a radioimmune assay procedure the cholesterol epoxide-nucleophile conjugate hapten may be labelled with a 25 radioactive element, such as tritium or carbon-14. Either the cholesterol epoxide or nucleophile component can be so labelled. As an example, tritium-labelled cholesterol can be converted to the cholesterol epoxides. Interaction of these with nucleophiles such as glutathione produces 30 tritium-labelled haptens. Also, by reacting a radioactively-labelled glutathione with cholesterol epoxide, the presence of the labelled glutathione nucleophile on the steroid nucleus may also be used as a basis for detection of the epoxide. Competition of added radio-labelled hapten 35 with that present in the test specimen for the

hapten-specific antibody serves as a basis for detection and quantitation.

The following examples represent preferred embodiments of the present invention:

EXAMPLE 1

Carbon-14 Labeled Cholesterol 5 α , 6 α -Epoxide

5 In a 25 ml. microflask fitted with a condenser 8 mg. (1 mCi, 20 μ mol) of 4-, ^{14}C - cholesterol (50 mCi/mmol) is dissolved in methylene chloride (5 ml). Treatment at 25°C for 30 minutes with m-chloroperbenzoic acid (25 μ mol) in methylene chloride (10 ml) solution is followed by the
10 dropwise addition of 10% aqueous sodium sulfite until a test with starch-iodide paper is negative for residual peracid. The reaction mixture transferred to a micro-separatory funnel is then washed with 5% aqueous sodium bicarbonate solution to remove the m-chlorobenzoic acid followed by aqueous saline washes. After evaporation of the solvent, the residue is crystallized from 88% aqueous acetone to give the desired 4- ^{14}C -cholesterol 5 α , 6 α epoxide (7 mg., 50 mCi/mmol). The radiolabeled product is diluted with unlabeled cholesterol 5 α , 6 α -epoxide to
15 desired specific radioactivity.
20

EXAMPLE 2

Tritium Labeled Cholesterol 5 α , 6 α -Epoxide

25 Following the procedures of Example 1, 5 mg. (1 Ci, 13 μ mol) of 1,2,6,7- ^3H -cholesterol (75 Ci/mmol) is treated with m-chloroperbenzoic (15 μ mol) in methylene chloride solution. The product is then recovered to yield 1,2,6,7- ^3H -cholesterol 5 α , 6 α -epoxide (4.5 mg, 75 Ci/mmol).